Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBV-TCR T cells in Chronic Hepatitis B
NCT05905731Phase 1Active, not recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Bone Marrow HSCs, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liocyx-m in Chronic Hepatitis B (CHB), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: Safety evaluation of HBV-TCR T cell treatment. Started Jun 2023; status: active, not recruiting.
02
Drugs
liocyx-m
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05905731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905731.